CONGRESS GUIDE
05.09.2016 • Views
Share Embed Flag

CONGRESS GUIDE

ExportFinalProgram_26082016041327

ExportFinalProgram_26082016041327

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
thromboadviser

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

ERS International Congress 2016<br />

DETAILED PROGRAMME<br />

TUESDAY 06 SEPTEMBER, 2016<br />

PA4056<br />

PA4057<br />

PA4058<br />

PA4059<br />

PA4060<br />

PA4061<br />

PA4062<br />

PA4063<br />

PA4064<br />

Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study<br />

Konstantinos Kostikas (Basel, Switzerland), Konstantinos Kostikas, Claus Vogelmeier, Timm Greulich, Jose M. Marin,<br />

Walter Castellani, Thomas Similowski, Vincent Ninane, Mina Gaga, Stephen Lane, Maryam Aalamian-Mattheis, Xavier<br />

Nunez, Andreas Clemens<br />

Assessing COPD profiles and outcomes by dyspnoea severity<br />

Antonio R. Anzueto (San Antonio, United States of America), Antonio R. Anzueto, Peter M.A. Calverley, Robert A. Wise,<br />

Achim Mueller, Norbert Metzdorf, Daniel Dusser<br />

Lung function, symptoms and prescription of inhaled steroids and long acting ² 2 agonists in patients managed by an<br />

integrated COPD team<br />

Angshu Bhowmik (Barnet, United Kingdom), Angshu Bhowmik, Arthur Tadique, Laura Graham, Matthew Hodson, Raj<br />

Rajakulasingam<br />

Onset of action of formoterol/budesonide (F/B) Spiromax® compared with F/B Turbuhaler® in patients with COPD:<br />

A preliminary report<br />

Josuel Ora (Rome, Italy), Josuel Ora, Alessandra Di Paolo, Gabriella Lucà, Luigino Calzetta, Paola Rogliani, Mario Cazzola<br />

Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in<br />

Indian patients<br />

Kshitij Mandke (Surat, India), Kshitij Mandke, Anup Mandke<br />

Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen<br />

complexity index<br />

Wei-Erh Cheng (Taichung, Taiwan), Wei Erh Cheng, Shan Chieh Wu, Sandy Ian-U. Chong, Jou Ying Chen, Hsiang-Wen<br />

Lin<br />

Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled<br />

analysis of 12 randomised trials<br />

John R Hurst (London, United Kingdom), John R. Hurst, Samy Suissa, Klaus F. Rabe, Giovanni Bader, Gerrit Zijlstra,<br />

Marcela Gavornikova, Francesco Patalano, Robert Fogel, Konstantinos Kostikas<br />

Patient characteristics of new initiators of glycopyrronium bromide (GLY) – A multinational, multi-database realworld<br />

drug-utilization study<br />

Katia MC Verhamme (Rotterdam, Netherlands), Katia M.C. Verhamme, Maria De Ridder, Lars Pedersen, Daniel Prieto-<br />

Alhambra, Francesco Lapi, Peter Rijnbeek, Rajeev K. Amar, Miriam Sturkenboom<br />

Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients<br />

Fabrizia Mariotti (Parma, Italy), Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Maxim Kots, Piotr Kuna<br />

PA4065<br />

Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients<br />

Mario Scuri (Parma, Italy), Elzbieta Hajol, Annalisa Piccinno, Isabelle Viaud, Isabella Montagna, Alessandro Guasconi,<br />

Stefano Vezzoli, Mario Scuri, Mike Polkey<br />

T-22 Session 599 12:50 - 14:40<br />

Thematic Poster: Novel avenues in the treatment of COPD II<br />

Chairs : Loes Kistemaker (Groningen, Netherlands), Adam Barczyk (Katowice, Poland), Leif Bjermer (Lund, Sweden), Timm Greulich<br />

(Marburg, Germany)<br />

PA4066<br />

Statins and mortality in COPD in the COMIC study: A prospective COPD cohort study<br />

Emanuel Citgez (Wierden, Netherlands), Emanuel Citgez, Job van der Palen, Paul van der Valk, Kirsten Koehorst-ter<br />

Huurne, Kris Movig, Marjolein Brusse-Keizer<br />

PA4067<br />

PA4068<br />

PA4069<br />

PA4070<br />

Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD<br />

Peter M. A. Calverley (Liverpool, United Kingdom), Peter M.A. Calverley, Emiel F.M. Wouters, Helen Finnigan, Kay<br />

Tetzlaff, Helgo Magnussen<br />

Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the<br />

metabolic syndrome<br />

Elena Blinova (Chelyabinsk, Chelyabinsk Oblast, Russian Federation), Elena Blinova, Galina Ignatova, Maria Belsner<br />

Glaucoma risk due to antimuscarinics, not a class effect: A systematic review<br />

Carlos Andrès Celis Preciado (Bogota, Cundinamarca, Colombia), Carlos Andrés Celis Preciado, Horacio Giraldo, Dario<br />

Londoño, Ingrid Rodriguez<br />

Direct cost analysis of COPD patients: A 1 year follow-up study<br />

Suleyman Savas Hacievliyagil (MALATYA, Turkey), Ünal Akel, Süleyman Savas Hacievliyagil, Zeynep Ayfer Aytemur,<br />

Saim Yologlu, Saltuk Bugra Kaya, Nazan Akel<br />

268 26.08.2016

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!